Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program

Abstract Introduction Ixekizumab, a highly selective interleukin-17A monoclonal antibody, was approved for the treatment of moderate-to-severe psoriasis (PsO) in 2016. Limited real-world data are available on its effectiveness from a patient’s perspective shortly (2 to 4 weeks) after initiation and...

全面介紹

書目詳細資料

發表在:	Dermatology and Therapy
Main Authors:	Alice B. Gottlieb, Russel Burge, William N. Malatestinic, Baojin Zhu, Yunyang Zhao, Julie McCormack, Miriam Kimel, Joseph F. Merola
格式:	Article
語言:	英语
出版:	Adis, Springer Healthcare 2023-07-01
主題:	Customer support program Ixekizumab Patient-reported outcomes Psoriasis
在線閱讀:	https://doi.org/10.1007/s13555-023-00969-1